Torsades de Pointes (TdP)

01Pathophysiology

Torsades de Pointes is a form of polymorphic ventricular tachycardia that occurs in the setting of a prolonged QT interval. This distinction is critical: not all polymorphic VT is TdP. The QT interval must be prolonged either at baseline or immediately preceding the arrhythmia for the diagnosis to apply.

The QT interval represents the total duration of ventricular depolarization and repolarization. Prolongation of this interval reflects delayed repolarization of ventricular cardiomyocytes. At the ionic level, this delay is caused by either a reduction in outward repolarizing potassium currents ($I_{Kr}I\_\{Kr\}$, $I_{Ks}I\_\{Ks\}$) or an increase in inward depolarizing currents (late sodium current $I_{Na}I\_\{Na\}$ or calcium current $I_{Ca,L}I\_\{Ca,L\}$). Most drug-induced QT prolongation involves blockade of the $I_{Kr}I\_\{Kr\}$ channel (encoded by the hERG gene), which is the rapid component of the delayed rectifier potassium current.

When repolarization is prolonged, the action potential duration increases. During this extended vulnerable window, L-type calcium channels can reactivate before the cell fully repolarizes, generating early afterdepolarizations (EADs). EADs are abnormal depolarizations that arise during phase 2 or phase 3 of the cardiac action potential. If an EAD reaches threshold, it triggers a premature ventricular complex (PVC). This PVC falls on the T-wave of the preceding beat, initiating the arrhythmia.

The characteristic short-long-short sequence that precedes TdP onset is a hallmark finding. A premature beat (short interval) is followed by a compensatory pause (long interval), which further prolongs repolarization. The next beat then arrives during the vulnerable period, triggering the tachycardia. This "pause-dependent" initiation explains why bradycardia is a risk factor for TdP, as slower heart rates prolong repolarization further.

The "twisting" morphology on ECG results from a rotating electrical axis of the QRS complex. The shifting amplitude of the QRS complexes above and below the baseline creates the characteristic waxing-and-waning spindle-shaped pattern. This occurs because different regions of the ventricle have heterogeneous repolarization times (called transmural dispersion of repolarization), leading to disorganized reentrant circuits.

TdP can self-terminate or it can degenerate into ventricular fibrillation and cardiac arrest. This is what makes it a life-threatening emergency.

02Classification and Clinical Manifestation

TdP is classified based on the underlying cause of QT prolongation:

Clinical manifestations vary by severity:

03Diagnostic Workup

The best initial test is a 12-lead ECG. You are looking for two things: the QTc interval and the morphology of any captured arrhythmia. The Bazett formula ($QTc=\frac{QT}{\sqrt{RR}}QTc\; =\; \backslash frac\{QT\}\{\backslash sqrt\{RR\}\}$) is the standard method for rate-correcting the QT interval. A QTc exceeding 500 ms is the threshold most associated with high arrhythmic risk.

During an active episode, the ECG will show polymorphic wide-complex tachycardia with the hallmark undulating axis. If the arrhythmia has already self-terminated by the time the ECG is obtained, the prolonged QT on the baseline tracing is what clinches the diagnosis. This is a common vignette setup: a patient presents after a syncopal episode, is now in sinus rhythm, and the ECG reveals a QTc of 540 ms.

Once TdP is identified or suspected, immediately check serum potassium, magnesium, and calcium. These are correctable risk factors, and replenishment is part of the acute treatment protocol. Concurrently, perform a thorough medication reconciliation. The question stem will often embed a recently started drug (sotalol, haloperidol, methadone, erythromycin) as the clue to the cause.

For patients with suspected congenital LQTS (young patient, family history of sudden death, no identifiable acquired cause), genetic testing serves as the confirmatory test. However, in the acute setting, clinical management does not wait for genetic results.

An echocardiogram should be obtained to rule out structural heart disease, which would point toward ischemia-related polymorphic VT rather than TdP.

04Management and Treatment

The first question is hemodynamic status. If the patient is pulseless, this is a cardiac arrest and you defibrillate immediately with unsynchronized shock. Do not delay for IV magnesium in a pulseless patient.

If the patient has a pulse but is in TdP, the next best step is IV magnesium sulfate 2 g bolus. This is the single most tested management point. Magnesium works by suppressing EADs and reducing the transmural dispersion of repolarization. It is effective regardless of the patient's baseline magnesium level. This is a common trap: students hesitate to give magnesium when the serum level is reported as normal. Give it anyway.

If magnesium fails to terminate the arrhythmia or episodes are recurrent, overdrive pacing is the next step. By pacing the heart at a faster rate (90 to 110 bpm), you shorten the action potential duration and the QT interval, eliminating the substrate for EADs. This is the definitive therapy for refractory TdP.

Isoproterenol, a beta-adrenergic agonist, can be used as a pharmacologic bridge to increase the heart rate while preparing for transvenous pacing. However, it is contraindicated in congenital LQT1 (where adrenergic triggers provoke events) and LQT3.

Simultaneously, discontinue the offending drug and correct electrolyte abnormalities aggressively. Target a potassium level at the higher end of normal (4.5 to 5.0 mEq/L) because higher extracellular potassium enhances repolarizing potassium currents and shortens the QT interval.

What NOT to do: Do not give amiodarone. Although amiodarone is a standard ACLS drug for other ventricular tachycardias, it prolongs the QT interval and will worsen TdP. This is one of the highest-yield "do not use" associations on the exam. Similarly, avoid all Class IA and Class III antiarrhythmics (procainamide, sotalol, dofetilide), as they all prolong QT.

For congenital LQTS, long-term management centers on beta-blockers (nadolol is preferred for LQT1 and LQT2) to blunt adrenergic surges and reduce event rates. An implantable cardioverter-defibrillator (ICD) is indicated for survivors of aborted sudden cardiac death or those with recurrent syncope despite medical therapy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on TdP questions is by selecting amiodarone as the treatment for a polymorphic ventricular tachycardia. The instinct is understandable because amiodarone is the go-to antiarrhythmic for most VT scenarios. However, in TdP, amiodarone prolongs the QT interval further and worsens the arrhythmia. The correct answer is IV magnesium sulfate. If you see polymorphic VT on a vignette, your immediate reflex should be to check the QT interval. If the QT is prolonged, it is TdP, and the answer is magnesium. If the QT is normal, it is likely ischemia-related polymorphic VT, and amiodarone becomes appropriate. That single branch point (prolonged QT vs. normal QT) determines the entire management pathway.

A second common trap involves the serum magnesium level. Some vignettes will report a normal magnesium level to distract you from giving magnesium. Do not fall for this. IV magnesium is given empirically for TdP regardless of serum levels because its therapeutic effect on membrane stabilization operates independently of baseline serum concentrations.

Third, watch for the congenital LQTS vignette disguised as a seizure case: a young patient with recurrent "seizures," a family history of sudden death, and a prolonged QT on ECG. The core competency here is recognizing that cardiac syncope from TdP can mimic seizures, and the correct next step is cardiac evaluation, not anticonvulsants.

Finally, remember the drug list. Vignettes will embed a QT-prolonging medication in the medication history (methadone in an opioid use disorder patient, haloperidol for agitation, erythromycin for pneumonia, ondansetron postoperatively). The question tests whether you can identify the offending agent and recognize its connection to the arrhythmia. Always read the medication list carefully when the vignette involves syncope, palpitations, or sudden cardiac arrest.